Intellia Therapeutics, Inc. (NTLA)

Intellia Therapeutics, Inc.'s Q·Score is 6.2/10 (Neutral), reflecting its current fundamentals, analyst data, and valuation metrics. Clean balance sheet with low leverage (0.1× debt-to-equity). Key area to monitor: low return on equity (-53%). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.

The consensus price target for NTLA is $26.71, based on ratings from 21 Wall Street analysts. This is 101.5% above the current price of $13.26. Price targets are forward-looking estimates and not guarantees of future performance.

Intellia Therapeutics, Inc. (NTLA) scores in line with sector averages on valuation metrics. The consensus analyst price target of $26.71 is 101% above the current price.

Intellia Therapeutics, Inc. is scheduled to report earnings in 4 days, on May 7, 2026.

Intellia Therapeutics, Inc. has a net profit margin of 0.0%, indicating the company is currently operating at a net loss. Its gross margin stands at 0.0%, reflecting a more cost-intensive business model.

Intellia Therapeutics, Inc. is reporting strong year-over-year growth of 78.8%.

Intellia Therapeutics, Inc. has a debt-to-equity ratio of 0.14×, reflecting a very low debt-to-equity ratio, signalling a conservatively financed balance sheet. Its current ratio is 5.08×, indicating comfortable short-term liquidity.